secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECISION BIOSCIENCES INC (DTIL)
CIK:        0001357874
Form:       8-K
Filed at:   2024-04-16T23:59:59+00:00
Accession:  0000950170-24-044831
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 1.02, 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precision BioSciences loses Lilly/Prevail collaboration; regains DMD, PBGENE-LLY2, PBGENE-LLY3 programs
--------------------------------------------------------------------------------

- Prevail (Lilly sub) terminated collaboration without cause effective July 10, 2024; Precision exercised reversion option to regain programs.
- Collaboration had generated up to $135M upfront; potential milestones up to $390-395M per product plus royalties are now lost.
- Preliminary Q1 2024 cash ~$137M; expected cash runway into H2 2026 unaffected (no Prevail milestones assumed).
- Precision claims strong proof-of-concept data: up to 45% gene insertion in non-dividing cells in NHP; plans to develop programs independently or with new partners.
- Near-term priorities (HBV, PMM, OTC partnership with iECURE) unchanged; IND/CTA submissions on track for 2024-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357874/000095017024044831/0000950170-24-044831-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357874/000095017024044831/dtil-20240411.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-044831

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer